Glenmark names CEO to head new N.J.-based subsidiary

Glenmark Pharmaceuticals, a global pharmaceutical company based in Mumbai, India, announced Monday it has appointed Alessandro Riva the CEO of its new subsidiary based in Paramus, effective April 2.

Riva is the current executive vice president, oncology therapeutics and cell therapy for Gilead Sciences.

Glenmark said Riva will head the new subsidiary as well as a management team and independent board of directors.

“We are pleased that Alessandro will assume the role of CEO of the new innovation business,” Glenn Saldanha, chairman and managing director, Glenmark Pharmaceuticals, said. “His extensive and diverse industry experience leading global R&D will no doubt be invaluable in driving our pipeline towards commercialization. We are excited for this major step as a company and are confident Alessandro’s talent and leadership will shape the innovation business into a major global biotech company.”

Prior to Gilead, Riva was at Novartis for 12 years, most recently serving as executive vice president and head of global oncology development and medical affairs in the Oncology Business Unit.  Before that, he held leadership roles with Rhône-Poulenc Rorer and Aventis, France.

“I’m excited to join a company so committed to driving business through entrepreneurial innovation. The novel technology and diverse pipeline, which includes clinical-stage candidates on track to progress rapidly, has the potential to differentiate in areas of unmet need,” Riva said. “I’m looking forward to bringing my experience to lead the company and work together with highly experienced teams to deliver first-in-class therapies to the patients who need them the most.”